NCT01003678终止1 期
A Phase I Study Evaluating the Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- To determine the safety, maximum tolerated dose (MTD) and recommended phase II dose of Clofarabine in patients with myelodysplastic syndrome (MDS).
研究概览
简要总结
This is a Phase I trial for patients with intermediate or high risk myelodysplastic syndrome (MDS).
The study agent, clofarabine, is produced by Genzyme Pharmaceuticals.
详细描述
The specific purpose of the study is to determine the safety, maximum tolerated dose (MTD) and recommended Phase II dose of clofarabine in patients with MDS.
- We will start at a dose of 1 mg daily.
- We will treat a group of 3 patients with clofarabine at that dose level.
- If there are no severe side effects seen at that dose level, then the next group of 3 patients will receive a higher dose.
- Treatment of groups of 3 patients will continue at higher dose levels until severe side-effects are noted.
- If more than 1 of the 3 patients experiences a severe side effect, dosing will be stopped at that level.
- If only one of the three patients experience a severe side effect, then three more patients will be treated, at that dose level and if they too experience severe side effects, then dose escalation will be stopped and the maximum tolerated dose will be determined.
- 10 more patients will be enrolled at the maximum tolerated dose.
- There will be up to 5 dose levels tested.
- We plan to test how much of the drugs are in the patient's blood at different times, and the levels of certain proteins in their blood.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide signed written informed consent.
- •Patients with MDS must have IPSS score that falls in the intermediate or high risk disease (intermediate 1 will have to be transfusion dependent).
- •Patients may have received up to two prior therapies for MDS including one hypomethylating agent and/or a biologic agent (biologic agents include GM-CSF or equivalent, danazol or equivalent, Sunitinib, Revlimid, ATG, or a vaccine).
- •Have adequate renal and hepatic functions as indicated by the following laboratory values:
- •Serum creatinine ≤ 1 mg/dL; if serum creatinine >l mg/dL, then the estimated glomerular filtration rate (GFR) must be >50 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease equation.
- •Serum bilirubin ≤1.5 mg/dL x upper limit of normal (ULN)
- •Aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 x ULN
- •Alkaline phosphatase ≤2.5 x ULN
- •Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
- •Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.
- •Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.
排除标准
- •Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.
- •Active CNS disease
- •Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
- •Pregnant or lactating patients.
- •Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
- •Have had any prior treatment with clofarabine
- •Have had a diagnosis of another malignancy, unless the patient has been disease free for at least 3 years following the completion of curative intent therapy, with the following exceptions:
- •Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed.
- •Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.
- •Have prior positive test for the Human Immunodeficiency Virus (HN).
- •Have prior positive test for the Human Immunodeficiency Virus (HN).
- •Have currently active gastrointestinal disease, or prior surgery that may affect the ability of the patient to absorb oral clofarabine.
- •Patients taking proton pump inhibitors such as omeprazole (Prilosec®), lansoprazole (Prevacid®), or esomeprazole (Nexium®). Those who cannot stop taking these drugs should be switched to H2 blockers such as famotidine (Pepcid®)or ranitidine (Zantac®).
- •Patients taking alternative medicines (such as herbal or botanical) are not permitted.
研究组 & 干预措施
Level 1
Experimental
1 mg daily for 5 consecutive days followed by 23 days off drug
干预措施: Clofarabine (Drug)
结局指标
主要结局
To determine the safety, maximum tolerated dose (MTD) and recommended phase II dose of Clofarabine in patients with myelodysplastic syndrome (MDS).
时间窗: Up to 6 months
次要结局
- To determine the efficacy of Clofarabine in patients with MDS(Up to 6 months)
- Determine the differences in clofarabine plasma levels following clofarabine treatment(Pre, Day 1: Hourly for 6 hours, Pre Day 5:Hourly for 5 hours)
- Evaluate the effect of clofarabine on DNA methylation(Pre and Day 1)
- To determine the differences in clofarabine triphosphate levels in cells following clofarabine treatment(Pre, Day 1: Hourly for 6 hours, Pre Day 5:Hourly for 5 hours)
- Estimate post-treatment p53R2levels in patients treated at the MTD (in the expanded cohort)(At 6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS PatientsMDSCMMLNCT04806906University of Florence11
招募中
2 期
A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDDMajor Depressive DisorderNCT06236880Gilgamesh Pharmaceuticals124
招募中
早期 1 期
Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid TumorsNeoplasmsNCT06346041Cancer Institute and Hospital, Chinese Academy of Medical Sciences19
已完成
2 期
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)Myelodysplastic SyndromesNCT01822691H. Lee Moffitt Cancer Center and Research Institute15
终止
1 期
Safety of SP-420 in the Treatment of Transfusional Iron OverloadIron OverloadNCT04741542The University of Texas Health Science Center at San Antonio2